वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
UnitedHealth Group Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $338.3B | |
|---|---|---|
| Revenue (ttm) | 450.1B | |
| Net income (ttm) | 15.9B | |
| EPS (ttm) | $17.5 | |
| Shares out | 897.6M | |
| P/E (trailing) | 23.3x | |
| P/E (forward) | 16.7x | |
| Dividend | $9.28 (2.28%) | |
| Volume | 2,955,783 | |
| Beta | 0.61 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $287.60B | $324.16B | $371.62B | $400.28B | $447.57B | +11.7% |
| Gross profit | $69.65B | $79.62B | $90.96B | $89.40B | $82.92B | +4.5% |
| Operating income | $23.97B | $28.44B | $32.36B | $32.29B | $18.96B | -5.7% |
| Net income | $17.29B | $20.12B | $22.38B | $14.41B | $12.06B | -8.6% |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 | -7.5% |
| EBITDA | $27.07B | $31.84B | $36.33B | $28.08B | $23.06B | -3.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $42.58B | $47.78B | $54.63B | $53.01B | $59.59B | +8.8% |
Recent company headlines from major financial publishers.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.0% | $553 | $592 | $643 | $717 | $833 |
| 7.0% | $473 | $494 | $521 | $556 | $603 |
| 8.0% | $420 | $433 | $448 | $468 | $492 |
| 9.0% | $381 | $389 | $399 | $411 | $426 |
| 10.0% | $351 | $357 | $364 | $372 | $381 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
